interferon induced protein with tetratricopeptide repeats 2Genealiases: G10P2 · GARG-39 · IFI-54 · IFI-54K · IFI54 · IFIT-2
Q-omics provides the consensus-scored IFIT2 profile across patient tissues and cancer cell-line models. IFIT2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IFIT2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, IFIT2 RNA expression shows 18,426 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, HNSC, and UVM as cancer lineages where IFIT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFIT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFIT2 survival associations across molecular data types. IFIT2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFIT2 RNA expression–survival associations across cancer types. High IFIT2 expression shows unfavorable associations in HNSC, but favorable associations in SKCM, KIRC, MESO, UCS and THCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IFIT2 RNA expression.
This table summarizes IFIT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IFIT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFIT2 shows lower tumor expression in LUAD, KICH and LUSC and higher tumor expression in HNSC, KIRC and THCA. The HNSC box plot shows higher IFIT2 RNA expression in tumor versus normal tissue (log2 FC = +3.216, t-test p < 0.001).
This table shows molecular features associated with IFIT2 in patient tissues and cancer cell lines. In patient samples, IFIT2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFIT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
